Работы, на которые ссылается эта работа

Работ: 199

Работа: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram, James Lee, Erik Hayman +4
Статья2012Цитирований: 2
ABI
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Mythili Koneru, Terence J. Purdon, David R. Spriggs +2
Статья2015Цитирований: 2
ABI
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang +17
Статья2009Цитирований: 2
ABI
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Stefani Spranger, Robbert M. Spaapen, Yuanyuan Zha +4
Статья2013Цитирований: 2
ABI
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal +33
Статья2016Цитирований: 2
ABI
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu, Mien‐Chie Hung
Обзорная статья2016Цитирований: 2
ABI
Tracking the Evolution of Non–Small-Cell Lung Cancer
Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicholas McGranahan +80
Статья2017Цитирований: 2
ABI
Tumor Heterogeneity in Breast Cancer
Gulisa Turashvili, Edi Brogi
Обзорная статья2017Цитирований: 2
ABI
Biomarker concordance between primary colorectal cancer and its metastases
Dilraj Bhullar, Jorge Barriuso, S. Mullamitha +3
Обзорная статья2019Цитирований: 2
ABI
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie +1
Обзорная статья2019Цитирований: 2
ABI
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38
Статья2020Цитирований: 2
ABI
Memory T cells: strategies for optimizing tumor immunotherapy
Qingjun Liu, Zhongjie Sun, Ligong Chen
Обзорная статья2020Цитирований: 2
ABI
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner, Rosalie M. Sterner
Обзорная статья2021Цитирований: 2
ABI
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27
Статья2021Цитирований: 2
ABI
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Brooke Prinzing, Caitlin C. Zebley, Christopher T. Petersen +24
Статья2021Цитирований: 2
ABI
A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy
Lupeng Ye, Jonathan J. Park, Lei Peng +17
Статья2022Цитирований: 2
ABI
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
Jinge Zhou, Lei Sun, Yujie Jia +8
Статья2022Цитирований: 2
ABI
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Zaoqu Liu, Zhaokai Zhou, Qin Dang +4
Обзорная статья2022Цитирований: 2
ABI
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute +4
Обзорная статья2022Цитирований: 2
ABI
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
Ting Yan, Lingfeng Zhu, Jin Chen
Обзорная статья2023Цитирований: 2
ABI
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody +8
Обзорная статья2023Цитирований: 2
ABI
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh +4
Обзорная статья2023Цитирований: 2
ABI
IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey +4
Статья2023Цитирований: 2
ABI
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech +17
Статья2023Цитирований: 2
ABI
Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors
Xiuxiu Zhu, Jun Chen, Wuling Li +8
Статья2023Цитирований: 2
ABI

Работы, на которые ссылается эта работа

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i>

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Up-Regulation of PD-L1, IDO, and T <sub>regs</sub> in the Melanoma Tumor Microenvironment Is Driven by CD8 <sup>+</sup> T Cells

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

Tracking the Evolution of Non–Small-Cell Lung Cancer

Tumor Heterogeneity in Breast Cancer

Biomarker concordance between primary colorectal cancer and its metastases

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

CRISPR-engineered T cells in patients with refractory cancer

Memory T cells: strategies for optimizing tumor immunotherapy

CAR-T cell therapy: current limitations and potential strategies

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy

Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors